DNDN charges the same price for its drug with the same result, but DNDN owns 100% of its drug, not 50% like MDVN. DNDN doesn't have to give 10% of its profits to UCLA. DNDN has more applications of its drug and its revenues are nearly double MDVN. MDVN lost its patent battle with generation 2 Xtandi, called ARN509.
ARN509 will be approved within a year and its doesn't cause seizures like Xtandi, and it is easier and cheaper to produce.